• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Perspective Therapeutics Inc.

    3/27/25 11:39:38 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care
    Get the next $CATX alert in real time by email
    S-8 1 form_s-8_-_march_2025.htm S-8 S-8

     

     

    As filed with the Securities and Exchange Commission on March 26, 2025

    Registration No. 333-

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    PERSPECTIVE THERAPEUTICS, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware

     

    41-1458152

    (State or Other Jurisdiction of Incorporation or Organization)

     

     

    (I.R.S. Employer Identification No.)

    2401 Elliott Avenue, Suite 320, Seattle, Washington

     

    98121

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

     

    Perspective Therapeutics, Inc. Third Amended and Restated 2020 Equity Incentive Plan

    (Full Title of the Plan)

     

     

    Johan (Thijs) Spoor

    Chief Executive Officer

    Perspective Therapeutics, Inc.

    2401 Elliott Avenue, Suite 320

    Seattle, Washington 98121

    (Name and Address of Agent For Service)

     

     

    (206) 676-0900

    (Telephone Number, Including Area Code, of Agent For Service)

     

     

    With Copies to:

    Andrew L. Strong, Esq.
    Stephen M. Nicolai, Esq.
    Hogan Lovells US LLP
    609 Main Street, Suite 4200
    Houston, Texas 77002
    (713) 632-1400

    Chris Nenno, Esq.

    General Counsel

    Perspective Therapeutics, Inc.

    2401 Elliott Avenue, Suite 320

     Seattle, Washington 98121

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

     

    Accelerated filer

    ☐

     

     

     

     

     

    Non-accelerated filer

    ☒

     

    Smaller reporting company

    ☒

     

     

     

     

     

     

     

     

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

    EXPLANATORY NOTE

    Pursuant to General Instruction E to Form S-8, this registration statement on Form S-8 is being filed by Perspective Therapeutics, Inc., a Delaware corporation (the “Registrant”), to register 3,533,573 additional shares of the Registrant’s common stock, $0.001 par value per share (the “Common Stock”), issuable under the Registrant’s Third Amended and Restated 2020 Equity Incentive Plan (the “2020 Plan”). These additional shares of Common Stock have become reserved for issuance as a result of the operation of the “evergreen” provision in the 2020 Plan, which provides that the total number of shares subject to the 2020 Plan will be increased on the first day of each fiscal year pursuant to a specified formula or a lesser number of shares as may be determined by the Registrant’s Board of Directors. Pursuant to General Instruction E to Form S-8, this registration statement incorporates by reference the contents of: (i) the registration statement on Form S-8 (File No. 333-281529) filed by the Registrant on August 14, 2024 relating to the 2020 Plan; (ii) the registration statement on Form S-8 (File No. 333-278412) filed by the Registrant on April 1, 2024 relating to the 2020 Plan; (iii) the registration statement on Form S-8 (File No. 333-273796) filed by the Registrant on August 8, 2023 relating to the 2020 Plan; (iv) the registration statement on Form S-8 (File No. 333-262413) filed by the Registrant on January 28, 2022 relating to the 2020 Plan; and (v) the registration statement on Form S-8 (File No. 333-236024) filed by the Registrant on January 23, 2020 relating to the 2020 Plan, in each case, except to the extent supplemented, amended or superseded by the information set forth herein.

     

     


     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents of the Registrant filed with the Securities and Exchange Commission (the “Commission”) are incorporated by reference in this registration statement as of their respective dates:

    •
    the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 26, 2025;
    •
    the Registrant’s Current Reports on Form 8-K (other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits accompanying such reports that are related to such items), filed with the Commission on January 6, 2025, January 13, 2025, January 24, 2025, February 3, 2025, March 4, 2025, March 17, 2025, and March 26, 2025; and
    •
    the description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A, filed with the Commission on April 12, 2007, as updated by Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, including any amendments or reports filed for the purpose of updating such description.

    All reports and other documents filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), but prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents, except for the documents, or portions thereof, that are “furnished” rather than filed with the Commission.

    For the purposes of this registration statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

     


     

    Item 8. Exhibits.

     

     

     

     

    Exhibit

    No.

     

    Description

    4.1

    Amended and Restated Certificate of Incorporation of Perspective Therapeutics, Inc. as of February 14, 2023, incorporated by reference to Exhibit 3.1 of the Form 8-K filed on February 16, 2023.

    4.2

     

    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Perspective Therapeutics, Inc., effective June 14, 2024, incorporated by reference to Exhibit 3.1 of the Form 8-K filed on June 14, 2024.

     

     

     

    4.3

    Amended and Restated Bylaws of Perspective Therapeutics, Inc. as of February 14, 2023, incorporated by reference to Exhibit 3.2 of the Form 8-K filed on February 16, 2023.

    4.4

     

    Perspective Therapeutics, Inc. Third Amended and Restated 2020 Equity Incentive Plan, incorporated by reference to Exhibit 10.1 of the Form 10-Q filed on August 13, 2024.

     

     

     

    5.1*

    Opinion of Hogan Lovells US LLP.

     

     

     

    23.1*

    Consent of Assure CPA, LLC, independent registered public accounting firm.

    23.2*

     

    Consent of WithumSmith+Brown, PC., independent registered public accounting firm.

     

     

     

    23.3*

    Consent of Hogan Lovells US LLP (included in Exhibit 5.1).

    24.1*

    Power of Attorney (included on signature page).

    107*

    Filing Fee Table.

     

    * Filed herewith.

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Seattle, State of Washington, on this 26th day of March, 2025.

     

     

    PERSPECTIVE THERAPEUTICS, INC.

     

     

     

     

    By:

    /s/ Johan (Thijs) Spoor

     

    Name:

     Johan (Thijs) Spoor

     

    Title:

    Chief Executive Officer

     

    POWER OF ATTORNEY

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Johan (Thijs) Spoor and Juan Graham as his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature

    Title

    Date

     

     

     

     

     

    /s/ Johan (Thijs) Spoor

     

    Chief Executive Officer & Director

    (Principal Executive Officer)

     

    March 26, 2025

    Johan (Thijs) Spoor

     

     

     

     

     

     

     

     

    /s/ Juan Graham

     

    Chief Financial Officer

     

    March 26, 2025

    Juan Graham

     

    (Principal Financial Officer)

     

     

     

     

     

     

     

    /s/ Jonathan Hunt

     

    Chief Accounting Officer

    (Principal Accounting Officer)

     

    March 26, 2025

    Jonathan Hunt

     

     

     

     

     

     

     

     

    /s/ Lori A. Woods

     

    Chairperson of the Board of Directors

     

    March 26, 2025

    Lori A. Woods

     

     

     

     

     

     

     

     

     

    /s/ Heidi Henson

     

    Director

     

    March 26, 2025

    Heidi Henson

     

     

     

     

     

     

     

     

     

    /s/ Frank Morich, M.D., Ph.D.

     

    Director

     

    March 26, 2025

    Frank Morich, M.D., Ph.D.

     

     

     

     

     

     

     

     

     

    /s/ Robert F. Williamson, III

     

    Director

     

    March 26, 2025

    Robert F. Williamson, III

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


    Get the next $CATX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CATX

    DatePrice TargetRatingAnalyst
    11/24/2025$12.00Buy
    Truist
    10/10/2025$14.00Buy
    BTIG Research
    3/13/2025$10.00Buy
    H.C. Wainwright
    3/7/2025$15.00Sector Outperform
    Scotiabank
    11/25/2024$24.00 → $5.00Buy → Neutral
    BofA Securities
    10/24/2024$20.00Buy
    UBS
    10/1/2024$25.00Outperform
    Wedbush
    9/25/2024$21.00Buy
    Truist
    More analyst ratings

    $CATX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Hunt Jonathan Robert bought $22,295 worth of shares (11,000 units at $2.03), increasing direct ownership by 23% to 59,800 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    11/17/25 8:01:56 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Director Williamson Robert F Iii bought $19,946 worth of shares (9,498 units at $2.10) (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    11/14/25 8:00:03 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Spoor Johan M. bought $59,673 worth of shares (26,676 units at $2.24), increasing direct ownership by 59% to 59,383 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    4/1/25 6:44:41 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist resumed coverage on Perspective Therapeutics with a new price target

    Truist resumed coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $12.00

    11/24/25 9:17:24 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    BTIG Research initiated coverage on Perspective Therapeutics with a new price target

    BTIG Research initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $14.00

    10/10/25 8:39:44 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright initiated coverage on Perspective Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $10.00

    3/13/25 7:26:51 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

    SEATTLE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today announced the pricing of an underwritten offering of 39,576,088 shares of its common stock at an offering price of $3.79 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 6,598,046 shares of its common stock at a price of $3.789 per pre-funded warrant. The aggregate gross proceeds from this offering are expected to be approximately $175 million, before deducting underwriting discounts and commissions and other offering expe

    2/2/26 8:35:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference

    Continued strong patient recruitment in neuroendocrine tumors for lead program VMT-α-NET sets the stage for submissions of robust clinical data package for presentation to more medical conferences in 2026, as well as regulatory engagementVMT-α-NET continues to be well-tolerated and shows durable disease control and deepening of tumor response with longer follow-up as reported at ASCO-GI 2026 Clinical updates expected in mid to late 2026 for VMT01 targeting melanoma and PSV359 targeting FAP across multiple solid tumors, as well as potential additions to the clinical pipeline to be guided by first-in-human imagesCompany to present updates at 44th Annual J.P. Morgan Healthcare Conference on

    1/12/26 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

    Updated interim results with an additional ~13 weeks of follow-up since the prior update[212Pb]VMT-α-NET continues to be well-tolerated Updated efficacy analysis suggests durable disease control and deepening of tumor response per RECIST v1.1 in the first 23 patients in Cohort 2 and both patients in Cohort 1Objective response in 39% of patients in Cohort 2 regardless of SSTR2 expression profile, including one Cohort 2 patient who experienced an initial objective response pending confirmation since the prior update, and 8 previously reported confirmed responders  Cohort 3 (6.0 mCi) dose limiting toxicities (DLT) assessment completed as planned; cleared to treat more patients with one addition

    1/9/26 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    SEC Filings

    View All

    $CATX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Perspective Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    2/3/26 4:07:20 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    SEC Form FWP filed by Perspective Therapeutics Inc.

    FWP - Perspective Therapeutics, Inc. (0000728387) (Subject)

    2/2/26 7:45:25 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    2/2/26 7:44:33 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Chief Accounting Officer Hunt Jonathan Robert bought $22,295 worth of shares (11,000 units at $2.03), increasing direct ownership by 23% to 59,800 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    11/17/25 8:01:56 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Director Williamson Robert F Iii bought $19,946 worth of shares (9,498 units at $2.10) (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    11/14/25 8:00:03 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Sendek Joel

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    9/5/25 4:06:51 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Financials

    Live finance-specific insights

    View All

    Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

    Updated interim results with an additional ~19 weeks of follow-up since the prior update [212Pb]VMT-α-NET continues to be well-tolerated Objective Response Rate of 44% (7 of 16 patients) in Cohort 2 with SSTR2 expression in all tumors at median follow-up of 41 weeks; 14 of the 16 patients remain free from progression and on studyInitial efficacy data pending for an additional 23 patients in Cohort 2 and 8 patients in Cohort 3, expected during 2026Perspective will hold a conference call on Monday, October 20, 2025 at 8:30 am ET SEATTLE, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering adv

    10/20/25 4:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

     Updated interim results with an additional ~16 weeks of follow-up on nine patients in Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) and initial safety findings in an additional 33 patients treated in Cohort 2 from the ongoing Phase 1/2a study were presented[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities and no discontinuations due to adverse events observed among a total of 42 patients who received at least one treatmentFour of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. Three of those patients experienced confirmed response and remained in response. One new first response is subject

    5/30/25 5:21:00 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

      Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding for [212Pb]VMT-α-NET[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested Three of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. First responses for two patients occurred after end of treatment period and are subject to confirmation, in addition to the previously reported patient with confirmed response who remains in response The five other patients in Coh

    1/24/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Perspective Therapeutics Inc.

    SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

    11/14/24 6:14:40 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

    SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)

    11/14/24 4:05:13 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

    SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)

    11/7/24 9:24:55 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $CATX
    Leadership Updates

    Live Leadership Updates

    View All

    Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer

    SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company's Chief Financial Officer, effective today. Mr. Sendek brings extensive experience in senior corporate roles in biotech finance and as a highly respected senior equity research analyst at a number of leading firms. Mr. Sendek previously served as CFO at four biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. He has a successful track record in corporate finance, having completed

    9/4/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

    SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that its Board of Directors has appointed Maya Martinez-Davis as an independent director to the Company's Board of Directors, effective today. Ms. Martinez-Davis currently serves as President of GSK's U.S. Commercial business, a position she has held since September 2019. In that role, she leads a robust and complex business portfolio of products in specialty, respiratory, oncology and vaccines. Prior to GSK, Ms. Martinez-Davis was President of biopharma Latin

    9/3/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

    Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot

    6/24/25 12:52:00 PM ET
    $AUTL
    $CATX
    $INDP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations